Eiger BioPharmaceuticals, Inc. updated on progress across its product pipeline, including clinical and regulatory program planned milestones, and commercial preparation. The company announced that rolling NDA submission of Lonafarnib in Progeria and Progeroid Laminopathies is planned to complete in first quarter of 2020. Marketing Authorization Application (MAA) is planned to EMA in first quarter of 2020. Lonafarnib in Hepatitis Delta Virus (HDV) Phase 3 D-LIVR Study enrollment is planned to complete in 2020 with topline data planned in 2021. Peginterferon Lambda (Lambda) in HDV End of Phase 2 meeting for Lambda monotherapy planned with FDA in first quarter of 2020. Additional Phase 2 LIFT data expected at EASL and AASLD 2020.